US009408863B2

(12) **United States Patent**
**Verma et al.**

(10) **Patent No.: US 9,408,863 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **5'-SUBSTITUTED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES**

(75) Inventors: **Vishal A. Verma**, Jersey City, NJ (US); **Ashok Arasappan**, Bridgewater, NJ (US); **F. George Njoroge**, Carmel, IN (US); **Kevin X. Chen**, Edison, NJ (US)

(73) Assignee: **Merck Sharp & Dohme Corp.**, Rahway, NJ (US)

( * ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 224 days.

(21) Appl. No.: **14/232,536**

(22) PCT Filed: **Jul. 10, 2012**

(86) PCT No.: **PCT/US2012/046038**

§ 371 (c)(1),
(2), (4) Date: **Apr. 11, 2014**

(87) PCT Pub. No.: **WO2013/009737**

PCT Pub. Date: **Jan. 17, 2013**

(65) **Prior Publication Data**

US 2014/0221304 A1 Aug. 7, 2014

**Related U.S. Application Data**

(60) Provisional application No. 61/507,364, filed on Jul. 13, 2011.

(51) **Int. Cl.**

| | |
|---|---|
| ***A01N 43/04*** | (2006.01) |
| ***A61K 31/70*** | (2006.01) |
| ***C07H 19/20*** | (2006.01) |
| ***C07H 19/10*** | (2006.01) |
| ***C07H 19/04*** | (2006.01) |
| ***C07H 19/048*** | (2006.01) |
| ***A61K 31/7056*** | (2006.01) |
| ***A01N 37/46*** | (2006.01) |
| ***C07H 19/06*** | (2006.01) |
| ***C07H 19/16*** | (2006.01) |
| ***A61K 31/341*** | (2006.01) |
| ***A61K 31/4196*** | (2006.01) |
| ***A61K 31/7068*** | (2006.01) |
| ***A61K 31/7072*** | (2006.01) |
| ***A61K 31/7076*** | (2006.01) |
| ***A61K 31/708*** | (2006.01) |
| ***A61K 45/06*** | (2006.01) |

(52) **U.S. Cl.**

CPC ..... ***A61K 31/7056*** (2013.01); ***A01N 37/46*** (2013.01); ***A61K 31/341*** (2013.01); ***A61K 31/4196*** (2013.01); ***A61K 31/708*** (2013.01); ***A61K 31/7068*** (2013.01); ***A61K 31/7072*** (2013.01); ***A61K 31/7076*** (2013.01); ***A61K 45/06*** (2013.01); ***C07H 19/06*** (2013.01); ***C07H 19/10*** (2013.01); ***C07H 19/16*** (2013.01); ***C07H 19/20*** (2013.01)

(58) **Field of Classification Search**

CPC . A01N 37/46; A61K 31/7072; A61K 31/341; A61K 31/4196; A61K 31/7076; A61K 31/708; A61K 45/06; A61K 31/7068; A61K 31/7056; A61K 2300/00; C07H 19/16; C07H 19/06; C07H 19/20; C07H 19/10

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

| | | | |
|---|---|---|---|
| 3,480,613 | A | 11/1969 | Walton |
| 1,187,824 | A | 4/1970 | Walton |
| 4,211,773 | A | 7/1980 | Lopez et al. |
| 4,666,892 | A | 5/1987 | Fox et al. |
| 4,808,614 | A | 2/1989 | Hertel |
| 5,672,594 | A | 9/1997 | Weis et al. |
| 5,837,852 | A | 11/1998 | Chung et al. |
| 5,977,061 | A | 11/1999 | Holy et al. |
| 6,063,628 | A | 5/2000 | Loeb et al. |

(Continued)

FOREIGN PATENT DOCUMENTS

| | | |
|---|---|---|
| FR | 1581628 | 9/1969 |
| WO | 9318051 | 9/1993 |

(Continued)

OTHER PUBLICATIONS

Mehta, et al., Biochemistry, 1976, pp. 4329-4333,vol. 15, No. 19.

Beers, et al., "The Merck Manual of Diagnosis and Therapy", 1999, Seventeenth Edition, pp. 377-386, 1132, 1280.

Chu, et al. "9-Deazaadenosine—A New Potent antitumor Agent", Biochemical Pharmacology, 1984, vol. 33, pp. 1229-1234.

Clark, et al., "Synthesis and Antiviral Activity of 2'-Deoxy-2'-Fluoro-2'-C-Methyl Purine Nucleosides As Inhibitors of Hepatitis C Virus RNA Replication", Bioorganic & Medicinal Chemistry Letters, 2006, vol. 16, pp. 1712-1715.

Dee Nord, et al., "Inhibition of Orotidylate Decarboxylase by 4(5H)-Oxo-1-B-D-Ribofuranosylpyrazolo[3,4-d] Pyrimidine-3-Thiocarboxamide (APR-TC) in B Lymphoblasts", Biochemical Pharmacology, 1988, vol. 37, pp. 4697-4705.

(Continued)

*Primary Examiner* — Lawrence E Crane

(74) *Attorney, Agent, or Firm* — Jeffrey P. Bergman; Catherine D. Fitch

(57) **ABSTRACT**

The present invention relates to 5'-Substituted Nucleoside Analogs of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, Z, $R^1$, $R^2$, $R^3$ and $R^{3'}$ are as defined herein. The present invention also relates to compositions comprising at least one 5'-Substituted Nucleoside Analog, and methods of using the 5'-Substituted Nucleoside Analogs for treating or preventing HCV infection in a patient.

(I)




**12 Claims, No Drawings**